News

Featured News

  • 2023 |
  • 2022 |
  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • Press Release | February 2, 2023

    Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

    Read More

    Press Release | February 1, 2023

    Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D

    Read More

    Press Release | January 31, 2023

    Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

    Read More

    Press Release | January 27, 2023

    Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Read More